Biography

Cheepsattayakorn graduated Doctor of Medicine from Chiang Mai Medical School, Chiang Mai University, Chiang Mai, Thailand in 1986. He then further had trained in Internal Medicine, Radiology, General Practice, Family Medicine, and Preventive Medicine at Chiang Mai  University  Medical School.  He  certified  numerous  Fellowships  from  the  Royal  Colleges  of  Physicians  of  London, Edinburgh  and Thailand, Royal College of Physicians and Surgeons of  Glasgow, American  College of Physicians, and American College of Chest Physicians. Presently, he serves  both Editor and Editorial Board Member and also referee of several international journals. He  has  very  high  experience  in  the  fields  of  Pulmonary Diseases  and  Tuberculosis  including  Infectious  Diseases.  He  has  numerous  scientific  publications  both  in  national  and  international  journals  and  books.Recently, he  published  scientific  papers, entitled  Parasitic  Pneumonia  and  Lung  Involvement ,  Lung  Cancer  Chemotherapy, New  Treatment  and  Related  Patents, Breath  Tests  in  Respiratory  and  Critical  Care  Medicine : From  Research  to  Practice  in  Current  Perspectives, Novel  Avian  Flu A (H7N9) : Clinical  and  Epidemiological  Aspects,  and  Management, and Novel  Avian  Flu A (H7N9)  Epidemic : A  China's  Lesson  Learned (Editorial), and  textbook  chapters, entitled Management  of  TB  in  HIV  Subjects : The  Experience  in  Thailand, Multidrug-Resistant  Tuberculosis-Diagnosis, Treatment, Management, and  Control, and Influence  of  Human  Leukocyte  Antigen  on  Susceptibility  of  Tropical  Pulmonary  Infectious  Diseases.  He  had  been  served  a  Director  of  the  10^th  Zonal  Tuberculosis  and  Chest  Diseases Center, Chiang  Mai, Thailand  for  a  long  time  and  presently  serve  as  Consultant  in  Respiratory  Medicine (Pulmonologist)  at  the  10^th  Zonal  Tuberculosis  and  Chest  Diseases Center, Chiang  Mai, Thailand; Deputy  Director  and  a  Senior  Expert  of  the  10^th  Office  of  Disease  Prevention  and  Control, Chiang  Mai, Thailand, Department  of  Disease  Control, Ministry  of  Public  Health, Thailand.

Research Interest

Novel Therapeutics in Lung Cancer, Nontuberculous mycobacterial infection in HIV- infected patients, Multidrug – resistant tuberculosis patterns in HIV-infected patients, Chemokine gene polymorphisms and their susceptibility to tuberculosis, Breath Tests in Respiratory and Critical Care Medicine, Tropical Infectious Diseases, Human Genetics and Infectious Disease, Environmental and Occupational Pulmonary Diseases    

Biography

Brian Wigdahl Ph.D is professor and chair of the Department of Microbiology & Immunology, director of the Institute for Molecular Medicine and Infectious Disease, and director of the institute’s Center for Molecular Virology and Translational Neuroscience.  The research efforts of the Department and Institute center on the diagnosis, treatment, and prevention of infectious, oncogenic, and inflammatory disease with a cumulative extramural research commitment of just over $60 million.He also serves as the executive director of the interdisciplinary graduate program in molecular medicine. An internationally recognized molecular virologist, He focuses his research on the molecular mechanisms, treatment, and prevention of immunologic abnormalities, cancer, and progressive neurologic disorders caused by members of the retrovirus family.  These include the human immunodeficiency virus and the human T cell leukemia virus type 1 (HTLV-1), the first human tumor virus discovered.  In particular, efforts are focused on the prevention of HIV sexual transmission and the HIV-induced neurologic complications of HIV/AIDS.  He has been funded by the National Institutes of Health for nearly 30 years, with total awards totaling more than $40 million.  Current funding includes three NIH R01 research grants and a component of an NIH P30 grant.  He is also Co-Director of a Interdisciplinary and Translational Research Training Program in NeuroAIDS designed for graduate students. He current total research commitment is approximately $6 million.  He graduated from Augsburg College in Minneapolis and received his doctorate in microbiology from the Medical College of Wisconsin.  A senior associate editor of the Journal of NeuroVirology, he also served as chair of the NIH NeuroAIDS and Other End-Organ Diseases Review Committee, served for six years as president of the International Society for NeuroVirology and currently serves as treasurer of the Society.  He is the 2013 recipient Pioneer in Neurovirology Award presented in recognition of outstanding individual achievement in the field of neurovirology and awarded by the International Society for NeuroVirology.

Research Interest

Molecular mechanisms, treatment, and prevention of immunologic abnormalities, cancer, and progressive neurologic disorders caused by members of the retrovirus family. These include the human immunodeficiency virus and the human T cell leukemia virus type 1 (HTLV-1), the first human tumor virus discovered.  In particular, efforts are focused on the prevention of HIV sexual transmission and the HIV-induced neurologic complications of HIV/AIDS. 

 

Biography

W John Martin is Medical Director of the Institute of Progressive Medicine, within MI Hope Inc., a non-profit United States public charity specializing in the study of viruses causing mental illnesses. He received his medical degree from the University of Sydney in 1965 and the PhD degree from the University of Melbourne in 1970. He is Board Certified in both Anatomic and Clinical Pathology with sub specialty qualifications in Immunopathology and in Medical Microbiology. Using molecular assays and specialized virus culture techniques, he pioneered research leading to the detection of stealth adapted viruses. These viruses are derived from conventional viruses but do not normally provoke an inflammatory response. This is because of the deletion or mutation of the major antigens normally targeted by the cellular immune system. The viruses can, nevertheless, be suppressed through an alternative cellular energy (ACE) pathway. Dr. Martin explains the ACE pathway in terms of a natural energy force termed KELEA (kinetic energy limiting electrostatic attraction). He has further shown that water and other materials can capture and transmit KELEA to living organisms, including humans, animals and plants. This has led to a new paradigm of energy based medicine and agriculture. He works in South Pasadena, California, USA.

Research Interest

Virology; Stealth adapted viruses; Herpes viruses; Cytomegalovirus; HIV; Biophysics; Cellular energy; Cellular immunity; Homeopathy; Complimentary and Alternative Medicine; Autism; Mental illnesses; Psychiatry; Neurology; Neuropathology; Water

Biography

Peng Yin, M.D., PhD is currently the Director, Global Scientific Affairs, Medical and Scientific Affairs, Diagnostics Research, Abbott. He received his M.D. from Tianjin Medical School, China and worked as a General Surgeon for 5 years; then received his PhD in Molecular Virology from University of Manitoba, Canada and postdoctoral training with Prof. David Knipe at Harvard University, Medical School. Prior joining Abbott, he worked as a Senior Scientist in biotech companies in USA. He  has patent, book chapter and publications in Nature publication, Cell and Journal of Virology. He was invited to give speeches in Scientific Symposia around the world, such as Australia NRL Annual Meeting, China National Liver Disease’s Laboratory Diagnosis and Clinics Conference. In addition, he is a honorary Professor, Tianjin Medical University Cardiovascular Institute, TEDA International Cardiovascular Hospital, IFCC Congresses and Conference Executive Committee Member and AACC Chair-elect, Industry Division.

Research Interest

HBV, HCV diagnostics, screening, mutations, therapeutic monitoring, Liver fibrosis and HCC due to viral hepatitis; HIV diagnostics, screening, new emerging HIV variants; HTLV.

Biography

Jocelyn Yelle, M.Sc., Ph.D., is a virologist specialized in Retroviruses and Herpesviruses, with a marked interest in antiviral drug discovery. Born in a small town near Montreal, Canada, he holds an M.Sc. and a Ph.D. degrees in Virology from the Armand-Frappier Institute, a Montreal-based research center modeled on the Pasteur Institute in Paris. During his M.Sc. studies, he investigated the role of endogenous Retroviruses in cell transformation in animal models, while his Ph.D. thesis focused on the ability of certain DNA sequences of human cytomegalovirus to immortalize and transform normal cells into cancer cells. As a postdoctoral fellow at the Clinical Research Institute of Montreal, he explored the ability of tumor suppressor genes to reverse the cancer state in cell culture.

He launched his academic career in the early 1990s, investigating HIV’s ability to establish persistent infections in human cell cultures. He then started collaborating with a chemist colleague, mounting a comprehensive, multidisciplinary research program focusing on small molecules as potential drugs for HIV/AIDS treatment. With his colleague, he later launched Pharmacor Inc., a small biopharmaceutical company, to pursue the same goals. Some of these molecules were eventually acquired by Merck & Co. for further development.

He is Founder and President of Antiviral InteliStrat Inc., a consultancy firm that provides scientific advices, analyses of research projects and counselling, locally and abroad, to biotech/pharma industriesand hospital-based organizations. The firm also owns a proprietary database that contains scientific information on antiviral drugs and vaccines, which can be accessed online upon subscription.

During his career, he has authored or co-authored over 34 peer-reviewed scientific publications and presented his research and results to national and international scientific meetings. His name also appears on 8 U.S. patents related to experimental drugs for HIV/AIDS.

Research Interest

Retroviruses, Herpesviruses, new viruses having the potential to cause pandemics or with high rate of mortality in humans, antiviral drug discovery, novel approaches to prevent or treat viral infections, research on virus-cancer relations

Biography

Josef Bodor completed his PhD from Institute of Molecular Genetics, Prague in the Department of Molecular Oncology. He completed his M. Sc in 1984 from University of J.E. Purkynje, Brno (Czech Rep). He is Senior Investigator, Institute of Experimental Medicine AS CR, v.v.i. EU Center of Excellence. He worked as Visiting Professor, Institute of Immunology, and Universitätmedizin JGU Mainz, Germany. He was Assistant Professor, Columbia University, College of Physicians and Surgeons, Department of Pathology, New York, NY, Assistant Professor of Medicine, Boston University, School of Medicine, Boston, MA. He was Instructor in Medicine at Harvard Medical School, Boston, MA. He has received many Honors and Awards in his career. He has patent rights for his inventions.

Research Interest

Hematopoetic stem cell (HSC), HSC therapy, CCR5D32, human immunodeficiency virus (HIV), graft-versus-host (GvHD) disease, CD4⁺ T regulatory cells (Tregs), CD4⁺ T conventional cells (Tcons), interleukin-2 (IL-2), cyclic AMP (cAMP), inducible cAMP early repressor (ICER)